# Plain RAG on Cornelia de Lange syndrome 6 (BRD4, OMIM:620568)
model: gemini-3.8-flash   generated: 2026-09-28 20:47

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `BRD4 gene Cornelia de Lange syndrome 6`

[1] **Non-Classic Cornelia de Lange Syndrome Due to BRD4 ...**  
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12650802/  
    by F Lonardo · 2025 · Cited by 2 — Patients with CdLS who have a pathogenic variant in the BRD4 gene are extremely rare. They represent less than 1% of the patients with CdLS.

[2] **620568 - CORNELIA DE LANGE SYNDROME 6; CDLS6**  
    https://omim.org/entry/620568  
    Cornelia de Lange syndrome (CDLS) is a genetically heterogeneous developmental disorder characterized by malformations affecting multiple systems.

[3] **Cornelia de Lange syndrome-associated mutations cause ...**  
    https://www.nature.com/articles/s41467-021-23500-6  
    by G Olley · 2021 · Cited by 31 — Recently, we identified a missense mutation in BRD4 associated with a Cornelia de Lange-like syndrome that reduces BRD4 binding to acetylated ...

[4] **Cornelia De Lange Syndrome 6 (CDLS6)**  
    https://www.malacards.org/card/cornelia_de_lange_syndrome_6  
    A Cornelia de Lange syndrome characterized by malformations affecting multiple systems that has material basis in heterozygous mutation in the BRD4 gene on ...

[5] **Cornelia de Lange syndrome 6**  
    https://www.alliancegenome.org/disease/DOID:0060970  
    A Cornelia de Lange syndrome characterized by malformations affecting multiple systems that has_material_basis_in heterozygous mutation in the BRD4 gene on ...

[6] **None**  
    https://disease-ontology.org/term/DOID:0060970  
    A Cornelia de Lange syndrome characterized by malformations affecting multiple systems that has_material_basis_in heterozygous mutation in the BRD4 gene on ...

## 2. The context handed to the model
```
[1] Non-Classic Cornelia de Lange Syndrome Due to BRD4 ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC12650802/
by F Lonardo · 2025 · Cited by 2 — Patients with CdLS who have a pathogenic variant in the BRD4 gene are extremely rare. They represent less than 1% of the patients with CdLS.

[2] 620568 - CORNELIA DE LANGE SYNDROME 6; CDLS6
https://omim.org/entry/620568
Cornelia de Lange syndrome (CDLS) is a genetically heterogeneous developmental disorder characterized by malformations affecting multiple systems.

[3] Cornelia de Lange syndrome-associated mutations cause ...
https://www.nature.com/articles/s41467-021-23500-6
by G Olley · 2021 · Cited by 31 — Recently, we identified a missense mutation in BRD4 associated with a Cornelia de Lange-like syndrome that reduces BRD4 binding to acetylated ...

[4] Cornelia De Lange Syndrome 6 (CDLS6)
https://www.malacards.org/card/cornelia_de_lange_syndrome_6
A Cornelia de Lange syndrome characterized by malformations affecting multiple systems that has material basis in heterozygous mutation in the BRD4 gene on ...

[5] Cornelia de Lange syndrome 6
https://www.alliancegenome.org/disease/DOID:0060970
A Cornelia de Lange syndrome characterized by malformations affecting multiple systems that has_material_basis_in heterozygous mutation in the BRD4 gene on ...

[6] None
https://disease-ontology.org/term/DOID:0060970
A Cornelia de Lange syndrome characterized by malformations affecting multiple systems that has_material_basis_in heterozygous mutation in the BRD4 gene on ...
```

## 3. The gene, from the sources

Cornelia de Lange syndrome 6 (CDLS6) is a genetically heterogeneous developmental disorder characterized by malformations affecting multiple body systems [2, 4]. The condition has a material basis in heterozygous mutations occurring in the *BRD4* gene [4, 5, 6]. The specific identity of the *BRD4* gene product and its complete function within the cell are not fully covered in the provided sources [3]. However, the provided text indicates that BRD4 normally engages in binding to acetylated targets in the cell [3]. Regarding how variants cause disease, a missense mutation in *BRD4* associated with a Cornelia de Lange-like syndrome has been shown to reduce BRD4 binding to these acetylated targets [3]. Overall, patients with Cornelia de Lange syndrome who carry a pathogenic variant in the *BRD4* gene are extremely rare, representing less than 1% of all individuals with the condition [1].

*tokens in 529, out 1457*

## 4. The gene, closed book (no sources; beware hallucinations)

The ***BRD4*** gene encodes **Bromodomain-containing protein 4**, an epigenetic "reader" and transcriptional regulator belonging to the BET (bromodomain and extraterminal domain) family. BRD4 recognizes and binds acetylated histones via its tandem bromodomains, recruiting transcriptional complexes (such as P-TEFb and Mediator) to promote RNA polymerase II phosphorylation and drive gene expression during cell growth and development.

In relation to **Cornelia de Lange syndrome 6 (CdLS6)**, BRD4 interacts directly with NIPBL, a core cohesin-loading factor mutated in classic CdLS. Heterozygous *de novo* loss-of-function variants, deletions, or dominant-negative alterations in *BRD4* disrupt this BRD4–NIPBL interaction. This impairs cohesin recruitment to enhancers and promoters, leading to genome-wide transcriptional dysregulation that produces the craniofacial dysmorphism, intellectual disability, and growth delays characteristic of CdLS.

The association of *BRD4* mutations with CdLS-like features was first described in **2018**.

**Citation:**  
Olley, G., Ansari, M., Bengani, H., *et al.* (2018). *BRD4 interacts with NIPBL and fragments of BRD4 can cause Cornelia de Lange–like syndrome.* **Nature Genetics**, 50(3), 329–332.

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P04)

Based on the provided sources, here is the clinical evaluation:

### 1. Patient Rule-In / Rule-Out Evaluation
The provided sources state only that Cornelia de Lange syndrome 6 (CDLS6) is a genetically heterogeneous developmental disorder characterized by "malformations affecting multiple systems" [2, 4, 5, 6] associated with heterozygous mutations in *BRD4* [3, 4, 5, 6], presenting as a "Non-Classic Cornelia de Lange Syndrome" [1] or "Cornelia de Lange-like syndrome" [3]. The sources provide **no** specific HPO terms, craniofacial descriptions, or organ-specific clinical diagnostic criteria. 

Because all 10 patients exhibit multisystem involvement:
* **P01:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P02:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P03:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P04:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P05:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P06:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P07:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P08:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P09:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].
* **P10:** Cannot be ruled in or ruled out; the sources provide no specific phenotypic features or HPO terms to confirm or exclude this profile [1, 2, 4].

---

### 2. Single Most Likely Patient and Probability
* **Most Likely Patient:** None can be distinguished over the others using only the sources. If forced to nominate one arbitrarily (e.g., **P04**), it cannot be justified over any other candidate based on the provided text.
* **Probability:** **10% (0.10)**. Because the sources provide no distinguishing clinical details beyond generic multisystem involvement [2, 4, 5, 6], each of the 10 patients has an equal 1-in-10 prior probability.

---

### 3. Facts Needed to Be Confident (Not in the Sources)
To make a confident diagnosis, the following information is required:
1. **Genetic testing data:** Confirmation of a heterozygous pathogenic variant/missense mutation in the *BRD4* gene, which is the material basis of CDLS6 [3, 4, 5, 6]. The sources do not include molecular data for any of the patients.
2. **Specific clinical/phenotypic criteria:** A detailed list of characteristic HPO terms or dysmorphic features defining the "non-classic" or "CdLS-like" phenotype associated with *BRD4* variants [1, 3]. The sources only state the generic descriptor "malformations affecting multiple systems" [2, 4, 5, 6].
3. **Differential diagnostic features:** Explicit clinical features that differentiate CDLS6 from other genetic conditions presented in the list (P01–P10), none of which are mentioned in the sources.

--------------------------------------------------------------------------------

### Round 2  (picked: P01)

Based strictly on the provided sources, here is the clinical genetic assessment:

### 1. Rule In / Rule Out Evaluation for Each Patient

The provided sources define Cornelia de Lange syndrome 6 (CDLS6) only as a developmental disorder characterized broadly by "malformations affecting multiple systems" [2, 4, 5, 6] caused by heterozygous mutations in the *BRD4* gene [3, 4, 5, 6], presenting as a "Non-Classic Cornelia de Lange Syndrome" [1] or "Cornelia de Lange-like syndrome" [3]. The sources provide **no** phenotypic HPO terms, specific dysmorphic features, or organ-specific clinical criteria [1–6]. 

Because every patient listed (P01–P10) exhibits multi-system developmental malformations, the sources do not provide sufficient clinical detail to rule in or rule out any of them:

* **P01**: **Cannot rule in or rule out** based on the sources [1–6].
* **P02**: **Cannot rule in or rule out** based on the sources [1–6].
* **P03**: **Cannot rule in or rule out** based on the sources [1–6].
* **P04**: **Cannot rule in or rule out** based on the sources [1–6].
* **P05**: **Cannot rule in or rule out** based on the sources [1–6].
* **P06**: **Cannot rule in or rule out** based on the sources [1–6].
* **P07**: **Cannot rule in or rule out** based on the sources [1–6].
* **P08**: **Cannot rule in or rule out** based on the sources [1–6].
* **P09**: **Cannot rule in or rule out** based on the sources [1–6].
* **P10**: **Cannot rule in or rule out** based on the sources [1–6].

---

### 2. Single Most Likely Patient and Probability

* **Most likely patient:** **Indeterminate** among P01–P10 (any single patient, such as **P01**, is equally likely to any other).
* **Probability:** **10% (0.10)**.

**Rationale:** The provided sources state only that CDLS6 is characterized by "malformations affecting multiple systems" [2, 4, 5, 6]. Because all 10 candidate profiles show multi-system involvement and the sources provide zero distinguishing clinical or HPO terms [1–6], there is no textual basis to assign a higher probability to any single individual. Given that exactly one patient has CDLS6, each patient has an equal prior probability of 1 in 10 (10%).

---

### 3. Facts Needed (and Not Provided in the Sources) to Be Confident

To establish a confident diagnosis using the sources, the following missing information would be required:
1. **Specific Phenotypic / HPO Profiles:** Detailed clinical manifestations, dysmorphic facial features, skeletal anomalies, or neurodevelopmental signs associated specifically with *BRD4*-related CDLS6, rather than solely the broad description "malformations affecting multiple systems" [2, 4, 5, 6].
2. **Phenotypic Delineation of Non-Classic CdLS:** Objective clinical criteria describing how "Non-Classic Cornelia de Lange Syndrome" [1] or "Cornelia de Lange-like syndrome" [3] differs phenotypically from classical CdLS and other syndromic mimics.
3. **Molecular / Genetic Data:** Confirmation of a heterozygous pathogenic variant in the *BRD4* gene for the specific patient, which is the defined material basis of CDLS6 [1, 3, 4, 5, 6].

--------------------------------------------------------------------------------

### Round 3  (picked: no clear pick)

Based on the provided sources, here is the clinical genetic evaluation:

### 1. Evaluation of Patients (P01–P10)
The provided sources state only that Cornelia de Lange syndrome 6 (CDLS6) is a "developmental disorder characterized by malformations affecting multiple systems" [2, 4, 5, 6], is "non-classic" or "Cornelia de Lange-like" [1, 3], is extremely rare (<1% of CdLS cases) [1], and is caused by heterozygous mutations in the *BRD4* gene [1, 3, 4, 5, 6]. 

Because the sources contain **no specific clinical features, facial characteristics, or HPO terms**:
* **P01:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P02:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P03:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P04:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P05:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P06:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P07:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P08:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P09:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].
* **P10:** Cannot be ruled in or ruled out; the sources provide no phenotypic details to evaluate these features [1–6].

---

### 2. Single Most Likely Patient and Probability
* **Most likely patient:** Based solely on the provided texts, **no single patient can be distinguished as more likely than any other**, as all 10 present with multisystem involvement consistent with "malformations affecting multiple systems" [2, 4, 5, 6]. Any chosen patient (e.g., P01) is an arbitrary selection.
* **Probability:** **10% (0.10)**, representing equal prior probability across the 10 candidates in the absence of distinguishing clinical data in the sources.

---

### 3. Facts Needed (and Not Provided in the Sources) to Be Confident
To confidently determine which patient has CDLS6, the following information is required:
1. **Specific clinical phenotype and HPO terms associated with *BRD4*/CDLS6:** The sources only describe it generally as "malformations affecting multiple systems" [2, 4, 5, 6] and "non-classic" [1] without specifying particular facial, limb, or neurodevelopmental features.
2. **Genetic sequencing results:** The sources state that CDLS6 is caused by heterozygous pathogenic variants in the *BRD4* gene [1, 3, 4, 5, 6], but no genetic testing data is provided for patients P01 through P10.
3. **Exclusion/differential diagnostic criteria:** Information distinguishing CDLS6 from other CdLS subtypes or overlapping syndromes is not provided in the sources [1–6].

--------------------------------------------------------------------------------

picks across rounds: ['P04', 'P01', None]
